作者
Domenica Lorusso, G Ferrandina, N Colombo, S Pignata, A Pietragalla, C Sonetto, C Pisano, MT Lapresa, A Savarese, P Tagliaferri, D Lombardi, S Cinieri, E Breda, I Sabatucci, R Sabbatini, C Conte, SC Cecere, G Maltese, Giovanni Scambia
发表日期
2019/12/1
期刊
Gynecologic oncology
卷号
155
期号
3
页码范围
406-412
出版商
Academic Press
简介
Objective
Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical data reported Bevacizumab effectiveness in EC both as single agent and in combination with chemotherapy.
Methods
In a phase II trial, patients with advanced (FIGO stage III-IV) or recurrent EC were randomized to receive Carboplatin-Paclitaxel standard dose for 6–8 cycles vs Carboplatin-Paclitaxel and Bevacizumab 15 mg/kg in combination with chemotherapy and maintenance until disease progression or unacceptable toxicity. The primary endpoint was progression free survival (PFS).
Results
108 patients were randomized; PFS (10.5 vs 13.7 months, HR 0.84 p = 0.43), overall response rate (ORR 53.1% vs 74.4%) and overall survival (OS) (29.7 vs 40.0 months, HR 0.71 p = 0.24) resulted in a non-significant increase in Bevacizumab treated …
学术搜索中的文章
D Lorusso, G Ferrandina, N Colombo, S Pignata… - Gynecologic oncology, 2019